Videos

Patients with relapsed/refractory diffuse large B-cell lymphoma who are unable to undergo autologous stem cell transplant have a new treatment option in the combination of Monjuvi and Revlimid. The lead researcher on the study that led to the combination’s approval discusses what patients need to know.

Dr. Lori A. Leslie discuses the potential of combination therapies with the emerging agent cirmtuzumab for patients with mantle cell lymphoma.

Dr. Nathan A. Pennell discusses the key genetic markers for treating patients with non-small cell lung cancer with targeted therapies.

Many factors impact outcomes in patients with advanced renal cell carcinoma, but recent findings suggest a patient’s age and gender are perhaps more important than previously realized.

Join us for our Chronic Lymphocytic Leukemia webinar where experts discuss CLL information highly relevant to patients, caregivers, advocates and discuss patient questions.

Despite recent advances in the treatment of multiple myeloma, more must be done to find effective treatment options for patients with advanced disease, according to Dr. Luciano J. Costa.

While the use of CAR-T cell therapy is currently still being investigated in patients with multiple myeloma, Dr. Nina Shah of the UCSF Helen Diller Family Comprehensive Cancer Center believes that these clinical trials will be what ultimately moves the field forward.

The future of multiple myeloma is heading toward combination therapies and CAR-T cell treatments, according to Dr. Betsy O'Donnell.

“Therapeutic trials are very, very important because thanks to them, our patients are living longer,” said Dr. Narjust Duma. “But (physicians) also need to stop and ask how our patients are living.”

Dr. Richard J. Gralla discusses some of the studies in supportive care that have been put on hold due to the ongoing COVID-19 pandemic.